View Post

Optimal Just-in-Time Service Changing the Paradigm of Cancer Trials

In Clinical Trials by Barbara Jacoby

From: businesswire.com First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America® (CTCA) are collaborating to speed patient enrollment in oncology clinical trials, enhancing patient access to potentially life-changing therapies and saving time in drug researchers’ quest to conquer …

View Post

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

In Clinical Trials by Barbara Jacoby

By: Sharon Begley From: statnews.com The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported on …

View Post

Leveraging Patient-Centric Data Analytics to Accelerate Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Crystal Black, Saama Technologies From: pharmavoice.com We are all familiar with the figures — it takes over a decade and $2.6 billion to bring a new drug to market. While these objective statistics are daunting and do give pause, almost every life science professional will agree that they don’t begin to tell the true story of the human element …

View Post

Sorry Princess Leia, but a Clinical Trial is My Only Hope

In Clinical Trials by Barbara Jacoby

By: Sarah DeBord From: curetoday.com I have two perspectives as I look at clinical trials: as the patient needing one and as an advocate encouraging patients to enroll in them. But how can I encourage someone to do something that I personally find so frustrating? Sarah DeBord was diagnosed with metastatic colon cancer at age 34. In the years since, …

View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

In Clinical Trials by Barbara Jacoby

Source: EnGeneIC Limited From: prnewswire.com EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the Company’s tumor-targeting, immunogenic EDVs™ to deliver a cytotoxic drug payload directly to tumors of patients who have exhausted curative treatment options. The …

View Post

Roswell Park Comprehensive Cancer Center Selects Circuit Clinical™ as a Collaborator for Groundbreaking CIMAvax Clinical Trial

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Circuit Clinical™ is proud to announce a unique collaboration with Roswell Park Comprehensive Cancer Center, to support the expansion of clinical trial opportunities to its outpatient oncology practices.  This collaboration marks Circuit Clinical’s entry into oncology clinical research, with both digital and clinical services. Circuit Clinical will be delivering both research operational support and TrialScout™ – its patient experience platform – in …

View Post

Perlmutter Cancer Center Expands Clinical Trials Program

In Clinical Trials by Barbara Jacoby

From: nyulangone.org Over the last five years, Perlmutter Cancer Center’s Clinical Trials Office (CTO) has tripled in size. With shortened opening times, expanded biobanking, a budding phase I clinical trials drug development program, new metric-tracking tools, and increased patient accrual across a growing clinical network, the CTO team has steadily grown and strengthened its relationships with pharmaceutical and biotech companies— …

View Post

Q&A: Epigenetic Therapies for Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Katarina Zimmer From: the-scientist.com Nancy Davidson is the senior vice president and director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, and has been studying the molecular mechanisms that drive breast cancer for the past three decades. In recent years, her lab has investigated the role of epigenetic changes that occur during the disease, and whether …

View Post

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Feasibility Study Intends to Quantify PRP’s Active Ingredients in Human Serum Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has initiated development of a bio-analytical assay intended to quantify the active ingredients of the company’s lead product candidate, PRP, in preparation …